TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics


TRACON Pharmaceuticals, Inc. (TCON): $1.35

-0.06 (-4.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TCON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TCON Stock Price Chart Interactive Chart >

Price chart for TCON

TCON Price/Volume Stats

Current price $1.35 52-week high $3.79
Prev. close $1.41 52-week low $1.24
Day low $1.31 Volume 89,500
Day high $1.42 Avg. volume 87,104
50-day MA $1.57 Dividend yield N/A
200-day MA $1.92 Market Cap 28.92M

TRACON Pharmaceuticals, Inc. (TCON) Company Bio


Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.


TCON Latest News Stream


Event/Time News Detail
Loading, please wait...

TCON Latest Social Stream


Loading social stream, please wait...

View Full TCON Social Stream

Latest TCON News From Around the Web

Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.

Revisiting TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON''s primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors. Read more to see TCON''s investment analysis.

Seeking Alpha | November 30, 2022

TRACON Pharmaceuticals (TCON) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) yesterday and set a price target of $8.00. The company's shares opened today at $1.44.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -37.8% and a 14.69% success rate on recommended stocks. Currently, the analyst consensus on TRACON Pharmaceuticals is a Strong Buy with an average price target of $8.33, representing a 478.47% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

Ryan Adist on TipRanks | November 22, 2022

H.C. Wainwright Sticks to Its Buy Rating for TRACON Pharmaceuticals (TCON)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) today and set a price target of $12.00. The company's shares opened today at $1.44.White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Valneva, and Spectrum Pharmaceuticals. According to TipRanks, White has an average return of -21.8% and a 26.45% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for TRACON Pharmaceuticals with a $8.33 average price target, which is a 478.47% upside from current levels.

Carrie Williams on TipRanks | November 21, 2022

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company’s CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubi

Yahoo | November 21, 2022

Maxim Group Remains a Buy on TRACON Pharmaceuticals (TCON)

Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON - Research Report) yesterday and set a price target of $8.00. The company's shares opened today at $1.51.According to TipRanks, McCarthy is an analyst with an average return of -38.2% and a 16.67% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals.Currently, the analyst consensus on TRACON Pharmaceuticals is a Strong Buy with an average price target of $8.33, representing a 451.66% upside. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $5.00 price target.

Jason Carr on TipRanks | November 16, 2022

Read More 'TCON' Stories Here

TCON Price Returns

1-mo -11.18%
3-mo -33.17%
6-mo -8.16%
1-year -50.55%
3-year -53.77%
5-year -95.50%
YTD -51.26%
2021 -76.32%
2020 400.00%
2019 -62.86%
2018 -81.19%
2017 -31.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6659 seconds.